Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
Plasmablastic multiple myeloma (PBM) is an aggressive multiple myeloma (MM) form, identified by a high risk of recurrence and poor prognosis, with limited effective treatment options. Present study reports a case initially diagnosed with IgG-kappa MM with double-hit genetics. Following induction che...
Saved in:
| Main Authors: | Lili Zhou, Paul Ning Man Cheng, Jian-qing Mi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567403/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01) -
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-05-01) -
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01) -
Two Cases of Plasmablastic Myeloma Mimicking Plasmablastic Lymphoma With In‐Depth Review of Literature
by: Sakiko Kitamura, et al.
Published: (2025-02-01) -
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
by: Liya Wei, et al.
Published: (2025-06-01)